Navigation Links
Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal

Mechanical 'artificial hearts' can be used to return severely failing hearts to their normal function, potentially removing the need for heart transplantation, according to new research.

The mechanical devices, known as Left Ventricular Assist Devices (LVADs), are currently used in patients with very severe heart failure whilst they await transplantation. The new study, published in the New England Journal of Medicine, shows that using an LVAD combined with certain drug therapies can shrink the enlarged heart and enable it to function normally once the LVAD is removed.

For the study, researchers from Imperial College London and the Royal Brompton and Harefield NHS Trust gave the full combination therapy to 15 severely ill patients. Of these 15, 11 recovered. Of these, 88 percent were free from recurrence of heart disease five years later. Their quality of life was measured as being at nearly normal.

Dr Emma Birks, from the Heart Science Centre at Imperial and the Royal Brompton and Harefield NHS Trust, and lead author of the study, said: "Donor heart transplant has for many years been the gold standard in the treatment of those with severe heart failure. It has proven greatly successful but is not without its shortcomings ?particularly the shortage of donor hearts and the risk of organ rejection.

"This therapy has the potential to ease the pressure on the waiting list while also offering patients a better alternative to a donor heart ?their own, healthy heart," she added.

Professor Sir Magdi Yacoub, from the Heart Science Centre at Imperial and the Royal Brompton and Harefield NHS Trust, said: "We are impressed by the dramatic, sustained improvement in the condition of these severely ill patients and we believe that this is due to the additive effects of the particular combination therapy used. The improvement observed was far greater than what has been reported to date for any other therapy in patients with severe,
'"/>

Source:Imperial College London


Page: 1 2

Related biology news :

1. UT Southwestern researchers find gene mutation that leads to broken hearts
2. Transgenic plants remove more selenium from polluted soil than wild plants, new tests show
3. Rare surgery performed to remove pancreas, prevent diabetes
4. First technology to remove prions that cause vCJD from blood launched
5. New UD technology removes viruses from drinking water
6. UCSD team discovers specialized, rare heart stem cells in newborns
7. Single stem cells from bone heal a broken heart
8. Python a hearty eater
9. Columbia study shows widely used artery clearing device does not help patients during heart attack
10. Researchers reveal secret of key protein in brain and heart function
11. Stem cell therapy successfully treats heart attack in animals

Post Your Comments:
(Date:11/4/2009).... 26 BIO-key Internation...inger-based biometric identification software is s...the AABB TXPO conference being held at the New Orl...O-key will provide hands-on product demonstrations... in booth #424. Also, at 5 PM on Monday, October 2...
(Date:11/3/2009)...BER 4, 2009 -- The world,s greatest wines are the..., human input, and something called the "terroir" ..., and climate. , Experts will discuss terroir ... Wednesday, Nov. 4 in Pittsburgh. "Terroir: Wineg...o parts at the 2009 Annual Meetings of the America...
(Date:11/3/2009)... Obese women are as much as 28 percent less likel...cy, according to research that earned a Michigan S...e findings by Barbara Luke, a researcher in the MS...rics, Gynecology and Reproductive Biology, focused...roductive technology. , Luke,s findings, which a...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Great wines come from great soils 2MSU researcher: Obesity significantly cuts odds of successful pregnancy 2Carefx Named an Innovative Information Access Company to Watch By Leading Market Research Firm 60229 1Carefx Named an Innovative Information Access Company to Watch By Leading Market Research Firm 60229 2Carefx Named an Innovative Information Access Company to Watch By Leading Market Research Firm 60229 3China Pharma Holdings Inc to Report Third Quarter 2009 Financial Results on November 12 2009 60226 1China Pharma Holdings Inc to Report Third Quarter 2009 Financial Results on November 12 2009 60226 2Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 1Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 2Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 3Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 4Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL 28TM 29 DosePro 28TM 29 60223 5
...for controlling a first key step in the creation o... the journal Nature tomorrow (Thursday 27 October ... early processes that take place once a sperm ente...ndamental process in sexually reproducing animals....ternal (mother,s) genome explains why eggs fail to...
...toxicological study on water-soluble buckyballs, r...cal and Environmental Nanotechnology (CBEN) find t...ly less toxic to begin with. Moreover, the researc...ndered nontoxic with minor chemical modifications....studies of water-soluble carbon nanotubes. The stu...
...ty of California, San Diego that appears in the Au...hat females of the species Uca crenulata may check...ows before finally deciding on a mate. , “As far a...ing nearly as many candidates as the California fi... the study while a doctoral student and a lecturer...
Other Biology News:Scientists unpick genetics of first 15 minutes of life 2Modifications render carbon nanotubes nontoxic 2Modifications render carbon nanotubes nontoxic 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3
(Date:11/6/2009)...Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech..."Company") today announced updated results from a ...nts with sarcomas metastatic to the lung in a post...ue Oncology Society Meeting held in Miami Beach, F...ntation, entitled "A Phase II Study of Intravenous...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 P...h is set to take place on February 22-24, 2010 in ...y conference we will highlight key issues in formi...are their experiences. , ...enda for Arrowhead’s 2010 Personalized Medi...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...Y, N.J., Nov. 5 DSM Pharmaceutical...acturing alliance with Galenix, Saint Jean D,Illac...al scale manufacturing partner for Galenix commerc...nix will collaborate on business development oppor...logies, based on the strength of Galenix in drug p...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...IA, Calif., April 28 MannKind,Corporation (Nasdaq...commercializing treatments for diabetes and cancer...an Stanley Healthcare Conference on Wednesday,Apri...Biscayne, Florida., Interested parties can access...n the Investor Relations section of the Company,s ...
...KNOLLS, N.J., April 28 Emisphere,Technologies, In...08 it,received a letter from the NASDAQ Stock Mark...st 10 consecutive trading days, the Company,s,mark...inimum $50,000,000,requirement for continued inclu...Q Marketplace Rule 4450(b)(1)(A). Furthermore, NAS...
...ND, Calif., April 28 Sangamo,BioSciences, Inc. (N...opment,of novel zinc finger DNA-binding proteins (...tion, announced today the nomination of Thomas G.,... Wiggans most recently served as Chief Executive O...ompany, from 1994, and as Chairman,of the Board fr...
Other Biology Technology:Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements 2Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4
GIBCO Streptomycin Sulfate from Invitrogen
GIBCO Dulbeccos Modified Eagle Medium (D-MEM) (1X); powder (low glucose) from Invitrogen
Goat Anti-Adducin beta (C-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rat TNF-alpha ELISA Kit, OptEIA from BD Biosciences Pharmingen
Biology Products: